Skip to main content
. 2022 Mar 8;9(3):e1153. doi: 10.1212/NXI.0000000000001153

Table 6.

Recommendations for the Dosing and Monitoring of Immunotherapeutic Agents in the Treatment of OMAS: Cyclophosphamide

graphic file with name NEURIMMINFL2021039579t6.jpg